Tel Aviv, Israel / Vancouver, Canada, May 22, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the selection of its first U.S. site for the company’s Phase I/

Source

Previous articlePsychedelics Weekly – Challenging the ‘Gifting’ Part of Prop 122, Public Perception in Oregon, and The Medicine of Music
Next articlePT411 – The Humanity of Healthcare Professionals, Ancient Psychedelic Use, and Breaking the Cycle of Colonialism